STOCK TITAN

Aldeyra Therapeutics (ALDX) director receives new stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aldeyra Therapeutics director Gary M. Phillips received three stock option grants. On the reported date, he was awarded options to buy 70,000, 6,636 and 4,977 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable on the one-year anniversary of the grant date, if he continues serving on the Board and its Compensation and Audit Committees as applicable.

Positive

  • None.

Negative

  • None.
Insider Phillips Gary M.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 70,000 $0.00 --
Grant/Award Stock Option (Right to Buy) 6,636 $0.00 --
Grant/Award Stock Option (Right to Buy) 4,977 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct, null)
Footnotes (1)
  1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Option grant size 70,000 options Stock Option (Right to Buy) grant, underlying common shares
Option grant size 6,636 options Stock Option (Right to Buy) grant, underlying common shares
Option grant size 4,977 options Stock Option (Right to Buy) grant, underlying common shares
Exercise price $1.72 per share Conversion or exercise price for each option grant
Expiration date June 8, 2036 Option expiration for all three grants
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Compensation Committee financial
"continuous service as a member of the Compensation Committee of the Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Audit Committee financial
"continuous service as a member of the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
continuous service financial
"provided that the Reporting Person provides continuous service as a member"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Phillips Gary M.

(Last)(First)(Middle)
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.7206/09/2026A70,000 (1)06/08/2036Common Stock70,000$070,000D
Stock Option (Right to Buy)$1.7206/09/2026A6,636 (2)06/08/2036Common Stock6,636$06,636D
Stock Option (Right to Buy)$1.7206/09/2026A4,977 (3)06/08/2036Common Stock4,977$04,977D
Explanation of Responses:
1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
3. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Gary Phillips06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aldeyra Therapeutics (ALDX) director Gary M. Phillips report on this Form 4?

Gary M. Phillips reported receiving three stock option grants. These options give him the right to buy Aldeyra common stock at a fixed price, reflecting equity-based compensation for his service on the Board and its key committees.

How many Aldeyra Therapeutics stock options were granted to Gary M. Phillips?

He was granted options on 70,000, 6,636 and 4,977 underlying shares of common stock. Each grant represents a separate award tied to his role on the Board of Directors and specific committees at Aldeyra Therapeutics.

What is the exercise price of the Aldeyra Therapeutics options granted to Gary M. Phillips?

All three option grants carry an exercise price of $1.72 per share. This means Phillips can purchase Aldeyra common stock at $1.72 if and when the options vest and he chooses to exercise them before expiration.

When do Gary M. Phillips’ Aldeyra stock options vest according to the Form 4?

Each option grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Vesting requires that Phillips continue to serve on the Board or relevant committee through the applicable vesting date.

What roles are tied to Gary M. Phillips’ Aldeyra Therapeutics option vesting conditions?

The vesting conditions reference his continuous service as a member of the Board of Directors, the Compensation Committee and the Audit Committee. Each grant relates to one of these roles and vests fully after one year of qualifying service.

When do the Aldeyra Therapeutics stock options granted to Gary M. Phillips expire?

Each option grant has an expiration date of June 8, 2036. After that date, any unexercised options will lapse, so Phillips must exercise vested options before that expiration to purchase Aldeyra common shares at the grant price.